Liệu pháp angiotensin II trong sốc nhiễm khuẩn kháng trị: Bệnh nhân nào có thể được lợi ích nhiều nhất? Một bài tổng quan

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287 Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND et al (2023) Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care 75:154258. https://doi.org/10.1016/j.jcrc.2023.154258 Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H et al (2018) The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med 44:857–867. https://doi.org/10.1007/s00134-018-5218-5 Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:e1063–e1143. https://doi.org/10.1097/CCM.0000000000005337 Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34:2226–2234. https://doi.org/10.1007/s00134-008-1219-0 Barabutis N, Marinova M, Solopov P, Uddin MA, Croston GE, Reinheimer TM et al (2020) Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction. J Pharmacol Exp Ther 375:286–295. https://doi.org/10.1124/jpet.120.000146 Chawla LS, Busse LW, Brasha-Mitchell E, Alotaibi Z (2016) The use of angiotensin II in distributive shock. Crit Care 20:137. https://doi.org/10.1186/s13054-016-1306-5 Corrêa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM (2014) Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med 42:e550-559. https://doi.org/10.1097/CCM.0000000000000397 Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 377:419–430. https://doi.org/10.1056/NEJMoa1704154 Ichihara A, Kobori H, Nishiyama A, Navar LG (2004) Renal renin-angiotensin system. Contrib Nephrol 143:117–130. https://doi.org/10.1159/000078716 Fyhrquist F, Saijonmaa O (2008) Renin-angiotensin system revisited. J Intern Med 264:224–236. https://doi.org/10.1111/j.1365-2796.2008.01981.x Kumar R, Singh VP, Baker KM (2007) The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 18:208–214. https://doi.org/10.1016/j.tem.2007.05.001 Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747–803. https://doi.org/10.1152/physrev.00036.2005 Jeyaraju M, McCurdy MT, Levine AR, Devarajan P, Mazzeffi MA, Mullins KE et al (2022) Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically Ill patients. Crit Care Med 50:50–60. https://doi.org/10.1097/CCM.0000000000005143 Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Van Meerhaeghe T, Brimioulle S et al (2019) Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit Care Med 47:152–158. https://doi.org/10.1097/CCM.0000000000003544 Kokkonen JO, Lindstedt KA, Kovanen PT (2003) Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? Circulation 107:2522–2524. https://doi.org/10.1161/01.CIR.0000074786.92067.AA Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-97. https://doi.org/10.1152/ajpcell.00287.2006 Fleming I, Kohlstedt K, Busse R (2006) The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens 15:8–13. https://doi.org/10.1097/01.mnh.0000196146.65330.ea Carey RM (2005) Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 14:67–71. https://doi.org/10.1097/00041552-200501000-00011 Baker KM, Booz GW, Dostal DE (1992) Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227–241. https://doi.org/10.1146/annurev.ph.54.030192.001303 Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl S12–22 https://doi.org/10.1046/j.1523-1755.62.s82.4.x Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA et al (2006) Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49:321–331. https://doi.org/10.1007/s00125-005-0101-7 Chu KY, Lau T, Carlsson P-O, Leung PS (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367–374. https://doi.org/10.2337/diabetes.55.02.06.db05-1022 Assimacopoulos-Jeannet FD, Blackmore PF, Exton JH (1982) Studies of the interaction between glucagon and alpha-adrenergic agonists in the control of hepatic glucose output. J Biol Chem 257:3759–3765 Del Greco F, Johnson DC (1961) Clinical experience with angiotensin II in the treatment of shock. JAMA 178:994–999. https://doi.org/10.1001/jama.1961.03040490020005 Derrick JR, Anderson JR, Roland BJ (1962) Adjunctive use of a biologic pressor agent, angiotensin, in management of shock. Circulation 25:263–267. https://doi.org/10.1161/01.cir.25.1.263 Wedeen R, Zucker G (1963) Angiotensin II in the treatment of shock. Am J Cardiol 11:82–86. https://doi.org/10.1016/0002-9149(63)90036-5 Singh S, Malhotra RP (1966) Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). J Assoc Physicians India 14:639–645 Thomas VL, Nielsen MS (1991) Administration of angiotensin II in refractory septic shock. Crit Care Med 19:1084–1086. https://doi.org/10.1097/00003246-199108000-00020 Jackson T, Corke C, Agar J (1993) Enalapril overdose treated with angiotensin infusion. Lancet 341:703. https://doi.org/10.1016/0140-6736(93)90479-z Lisinopril overdose and management with intravenous angiotensin II - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/7841571/ (Accessed 24 Nov 2023) Newby DE, Lee MR, Gray AJ, Boon NA (1995) Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol 40:103–104. https://doi.org/10.1111/j.1365-2125.1995.tb04546.x Ryding J, Heslet L, Hartvig T, Jønsson V (1995) Reversal of “refractory septic shock” by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest 107:201–203. https://doi.org/10.1378/chest.107.1.201 Wray GM, Coakley JH (1995) Severe septic shock unresponsive to noradrenaline. Lancet 346:1604. https://doi.org/10.1016/s0140-6736(95)91933-3 Tovar JL, Bujons I, Ruiz JC, Ibañez L, Salgado A (1997) Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron 77:239. https://doi.org/10.1159/000190280 Desachy A, Normand S, François B, Cassat C, Gastinne H (2000) Vignon P [Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II]. Presse Med 29:696–698 Yunge M, Petros A (2000) Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child 82:388–389. https://doi.org/10.1136/adc.82.5.388 Ammar MA, Ammar AA, Wieruszewski PM, Bissell BD, T Long M, Albert L et al (2022) Timing of vasoactive agents and corticosteroid initiation in septic shock. Ann Intensive Care 12:47. https://doi.org/10.1186/s13613-022-01021-9 Chawla LS, Ostermann M, Forni L, Tidmarsh GF (2019) Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care 23:124. https://doi.org/10.1186/s13054-019-2420-y Wakefield BJ, Sacha GL, Khanna AK (2018) Vasodilatory shock in the ICU and the role of angiotensin II. Curr Opin Crit Care 24:277–285. https://doi.org/10.1097/MCC.0000000000000517 Zhong L, Ji X-W, Wang H-L, Zhao G-M, Zhou Q, Xie B (2020) Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials. J Intensive Care 8:83. https://doi.org/10.1186/s40560-020-00500-0 Wieruszewski PM, Khanna AK (2022) Vasopressor Choice and Timing in Vasodilatory Shock. Crit Care 26:76. https://doi.org/10.1186/s13054-022-03911-7 Leone M, Einav S, Antonucci E, Depret F, Lakbar I, Martin-Loeches I et al (2023) Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pain Med 42:101193. https://doi.org/10.1016/j.accpm.2023.101193 Auchet T, Regnier M-A, Girerd N, Levy B (2017) Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care 7:43. https://doi.org/10.1186/s13613-017-0261-x Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R et al (2013) Survival after shock requiring high-dose vasopressor therapy. Chest 143:664–671. https://doi.org/10.1378/chest.12-1106 Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen J-T, Phillips KM et al (2020) Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock. Crit Care Med 48:1445–1453. https://doi.org/10.1097/CCM.0000000000004476 Sato R, Duggal A, Sacha GL, Rudoni MA, Yataco AC, Khanna AK et al (2023) The relationship between norepinephrine equivalent dose of vasopressors within 24 hours from the onset of septic shock and in-hospital mortality Rate. Chest 163:148–151. https://doi.org/10.1016/j.chest.2022.07.018 Sviri S, Hashoul J, Stav I, van Heerden PV (2014) Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care 29:157–160. https://doi.org/10.1016/j.jcrc.2013.09.004 See EJ, Clapham C, Liu J, Khasin M, Liskaser G, Chan JW et al (2023) A pilot study of angiotensin ii as primary vasopressor in critically ill adults with vasodilatory hypotension: the Aramis study. Shock 59:691–696. https://doi.org/10.1097/SHK.0000000000002109 Coulson TG, Miles LF, Serpa Neto A, Pilcher D, Weinberg L, Landoni G et al (2022) A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery. Anaesthesia 77:999–1009. https://doi.org/10.1111/anae.15802 Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS et al (2021) Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. J Cardiothorac Vasc Anesth 35:51–58. https://doi.org/10.1053/j.jvca.2020.08.001 Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA et al (2022) A multicenter observational cohort study of angiotensin ii in shock. J Intensive Care Med 37:75–82. https://doi.org/10.1177/0885066620972943 Bird S, Chand M, Tran TL, Ali S, Awad SS, Cornwell LD et al (2023) Evaluation of the addition of angiotensin II in patients with shock after cardiac surgery at a veterans affairs medical center. Ann Pharmacother 57:141–147. https://doi.org/10.1177/10600280221099928 Evans A, McCurdy MT, Weiner M, Zaku B, Chow JH (2019) Use of angiotensin II for post cardiopulmonary Bypass Vasoplegic Syndrome. Ann Thorac Surg 108:e5-7. https://doi.org/10.1016/j.athoracsur.2018.11.047 Konkol SB, Morrisette MJ, Hulse MC, Enfield KB, Mihalek AD (2022) Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: a case series. Ann Card Anaesth 25:359–361. https://doi.org/10.4103/aca.aca_98_21 Trethowan B, Michaud CJ, Fifer S (2020) Use of angiotensin II in severe vasoplegia after left pneumonectomy requiring cardiopulmonary bypass: a renin response analysis. Crit Care Med 48:e912–e915. https://doi.org/10.1097/CCM.0000000000004502 Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED (2019) Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock. J Cardiothorac Vasc Anesth 33:3080–3084. https://doi.org/10.1053/j.jvca.2019.03.004 Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK (2021) Angiotensin II for critically ill patients with shock after heart transplant. J Cardiothorac Vasc Anesth 35:2756–2762. https://doi.org/10.1053/j.jvca.2020.07.087 Wieruszewski PM, Sims CR, Daly RC, Taner T, Wittwer ED (2019) Use of angiotensin II for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology. J Cardiothorac Vasc Anesth 33:2366–2367. https://doi.org/10.1053/j.jvca.2019.03.054 Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K (2018) Angiotensin in ECMO patients with refractory shock. Crit Care 22:288. https://doi.org/10.1186/s13054-018-2225-4 Meersch M, Weiss R, Massoth C, Küllmar M, Saadat-Gilani K, Busen M et al (2022) The association between angiotensin ii and renin kinetics in patients after cardiac surgery. Anesth Analg 134:1002–1009. https://doi.org/10.1213/ANE.0000000000005953 Montgomery ML, Gross CR, Lin H-M, Ouyang Y, Levin MA, Corkill HE et al (2023) Plasma Renin Activity Increases With Cardiopulmonary Bypass and is Associated With Vasoplegia After Cardiac Surgery. J Cardiothorac Vasc Anesth 37:367–373. https://doi.org/10.1053/j.jvca.2022.11.019 Coulson TG, Miles LF, Zarbock A, Burrell LM, Patel SK, von Groote T et al (2023) Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial. Br J Anaesth 131:664–672. https://doi.org/10.1016/j.bja.2023.06.056 Küllmar M, Saadat-Gilani K, Weiss R, Massoth C, Lagan A, Cortés MN et al (2021) Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients. Am J Respir Crit Care Med 203:1119–1126. https://doi.org/10.1164/rccm.202005-2050OC Chow JH, Wittwer ED, Wieruszewski PM, Khanna AK (2022) Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients. J Thorac Cardiovasc Surg 163:1407–1414. https://doi.org/10.1016/j.jtcvs.2021.02.097 Busse LW, Barker N, Petersen C (2020) Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care 24:36. https://doi.org/10.1186/s13054-020-2743-8 Senchenkova EY, Russell J, Almeida-Paula LD, Harding JW, Granger DN (2010) Angiotensin II-mediated microvascular thrombosis. Hypertension 56:1089–1095. https://doi.org/10.1161/HYPERTENSIONAHA.110.158220 Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W (2005) Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 93:1069–1076. https://doi.org/10.1160/TH04-10-0701 Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M et al (2015) The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus 13:559–568. https://doi.org/10.2450/2015.0277-14 Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM et al (2021) Angiotensin II infusion for shock: a multicenter study of postmarketing use. Chest 159:596–605. https://doi.org/10.1016/j.chest.2020.08.2074 Szerlip H, Bihorac A, Chang S, Chung K, Hästbacka J, Murugan R et al (2018) 6: effect of disease severity on survival in patients receiving angiotensin ii for vasodilatory shock. Crit Care Med 46:3. https://doi.org/10.1097/01.ccm.0000528062.45598.be Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK et al (2023) Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care 27:175. https://doi.org/10.1186/s13054-023-04446-1 Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J et al (2022) Effectiveness of angiotensin ii for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor 4:e0623. https://doi.org/10.1097/CCE.0000000000000623 Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR et al (2018) Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 46:949–957. https://doi.org/10.1097/CCM.0000000000003092 38th International Symposium on Intensive Care and Emergency Medicine - PMC n.d. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883106/ (Accessed 24 Nov 2023) Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R et al (2020) Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care 24:227. https://doi.org/10.1186/s13054-020-02928-0 Leisman DE, Mastroianni F, Fisler G, Shah S, Hasan Z, Narasimhan M et al (2020) Physiologic response to angiotensin II treatment for coronavirus disease 2019-induced vasodilatory shock: a retrospective matched cohort study. Crit Care Explor 2:e0230. https://doi.org/10.1097/CCE.0000000000000230 Serpa Neto A, Landoni G, Ostermann M, Lumlertgul N, Forni L, Alvarez-Belon L et al (2022) Angiotensin II infusion in COVID-19: an international, multicenter, registry-based study. J Med Virol 94:2079–2088. https://doi.org/10.1002/jmv.27592 Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW et al (2020) Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med 202:1253–61. https://doi.org/10.1164/rccm.201911-2172OC Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM et al (2017) Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med 45:1285–1294. https://doi.org/10.1097/CCM.0000000000002441